Sharism- Lifestyle
Author:
Aptevo Therapeutics
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
Aptevo Provides State of the Business Report and 2025 Financial Results
March 26, 2026
Aptevo to Participate in March 2026 Conferences
March 19, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
March 10, 2026